Compared side by side
CagriSema vs tirzepatide: how they differ
The short answer
Both are weekly shots that pair GLP-1 with a second hormone: CagriSema combines semaglutide (GLP-1) with cagrilintide, an amylin analogue, and tirzepatide is one molecule that activates the GLP-1 and GIP receptors. Tirzepatide is FDA-approved, as Mounjaro and Zepbound; CagriSema isn’t approved yet, and Novo Nordisk filed it with the FDA in December 2025. In their own trials, CagriSema averaged about 20% weight loss at 68 weeks, and tirzepatide’s 15 mg up to 22.5% at 72 weeks (SURMOUNT-1).
Side by side
| Compared | CagriSema | Tirzepatide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Cagrilintide/semaglutide, Cagrilintide-semaglutide, Cagri-Sema, Cagri + Sema | Mounjaro, Zepbound, LY3298176 |
| What it is | Two weekly drugs in one regimen: cagrilintide, a long-acting version of the fullness hormone amylin, and semaglutide, the GLP-1 drug in Wegovy and Ozempic. | The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). |
| How it works | Weekly combination of two long-acting hormone analogues: cagrilintide, an amylin analogue that acts on amylin and calcitonin receptors, and semaglutide, a GLP-1 receptor agonist. Amylin and GLP-1 curb appetite through partly different brain pathways, so their effects add up: in REDEFINE 1 the pair lost more weight than either drug alone. Doses are written per component (2.4 mg/2.4 mg is 2.4 mg of each). Not approved: Novo Nordisk filed it with the FDA in December 2025, and a decision is expected in the fourth quarter of 2026. | Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management. |
| Commonly reported | Strong appetite suppression and early fullness, with nausea, vomiting or constipation through the dose steps. In its main trial people lost about 20% of body weight on average at 68 weeks, more than on semaglutide alone; it is not approved yet. | Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound). |
| Studied range | Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation. | FDA label: 2.5–15 mg, starting dose 2.5 mg. |
| How often | Weekly | Weekly |
| Half-life | ~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial) | ~5 days (FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | Studied as an ongoing weekly treatment: 68 to 84 weeks in phase 3. Not approved yet; Novo Nordisk filed for US approval in December 2025. | FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, vomiting, diarrhea, constipation, abdominal pain | Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue |
- Category
- CagriSemaMetabolic & GLP-1
- TirzepatideMetabolic & GLP-1
- Also known as
- CagriSemaCagrilintide/semaglutide, Cagrilintide-semaglutide, Cagri-Sema, Cagri + Sema
- TirzepatideMounjaro, Zepbound, LY3298176
- What it is
- CagriSemaTwo weekly drugs in one regimen: cagrilintide, a long-acting version of the fullness hormone amylin, and semaglutide, the GLP-1 drug in Wegovy and Ozempic.
- TirzepatideThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).
- How it works
- CagriSemaWeekly combination of two long-acting hormone analogues: cagrilintide, an amylin analogue that acts on amylin and calcitonin receptors, and semaglutide, a GLP-1 receptor agonist. Amylin and GLP-1 curb appetite through partly different brain pathways, so their effects add up: in REDEFINE 1 the pair lost more weight than either drug alone. Doses are written per component (2.4 mg/2.4 mg is 2.4 mg of each). Not approved: Novo Nordisk filed it with the FDA in December 2025, and a decision is expected in the fourth quarter of 2026.
- TirzepatideDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.
- Commonly reported
- CagriSemaStrong appetite suppression and early fullness, with nausea, vomiting or constipation through the dose steps. In its main trial people lost about 20% of body weight on average at 68 weeks, more than on semaglutide alone; it is not approved yet.
- TirzepatideVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).
- Studied range
- CagriSemaResearch range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.
- TirzepatideFDA label: 2.5–15 mg, starting dose 2.5 mg.
- How often
- CagriSemaWeekly
- TirzepatideWeekly
- Half-life
- CagriSema~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial)
- Tirzepatide~5 days (FDA label)
- Route
- CagriSemaSubQ injection
- TirzepatideSubQ injection
- Typical run
- CagriSemaStudied as an ongoing weekly treatment: 68 to 84 weeks in phase 3. Not approved yet; Novo Nordisk filed for US approval in December 2025.
- TirzepatideFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.
- Evidence
- CagriSemaEstablished: clinical trials or FDA-approved use exists
- TirzepatideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- CagriSemaNausea, vomiting, diarrhea, constipation, abdominal pain
- TirzepatideNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
CagriSema
- Day 1–28 · 0.25 mg The 0.25 mg start
- Day 29–364 · 0.5 mg 0.5 mg of each
- Day 57–364 · 1 mg 1 mg of each, halfway up
- Day 85–364 · 1.7 mg 1.7 mg of each, one step from the top
- Day 113+ · 2.4 mg 2.4 mg/2.4 mg, the maintenance dose
Tirzepatide
- Day 1–28 · 2.5 mg Getting your gut acclimated
- Day 29–56 · 5 mg First therapeutic dose — weight drops
- Day 57–112 · 7.5 mg Dual agonism in full effect
- Day 113–168 · 12.5 mg Max titration reached
- Day 169–504 Weeks 24 to 72: where most people plateau
- Day 365+ A maintenance medication, not a course
Questions people ask
How long do CagriSema and tirzepatide last?
The half-life of CagriSema is ~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial). The half-life of tirzepatide is ~5 days (FDA label).
How often are CagriSema and tirzepatide taken?
CagriSema: weekly. Route: SubQ injection. Tirzepatide: weekly. Route: SubQ injection.
How are CagriSema and tirzepatide dosed in research?
The research range for CagriSema is 0.25–2.4 mg, with a 0.25 mg starting dose. Studied in research — not a recommendation. The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose.
What are the common side effects of CagriSema and tirzepatide?
For CagriSema, the library lists: nausea, vomiting, diarrhea, constipation, abdominal pain. For tirzepatide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue.